Silence Therapeutics
UK business
Silence Therapeutics (Nasdaq: SLN) is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
Development
Silence Therapeutics develops medicines related to RNA interference or RNAi to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver.
Silence Therapeutic's product candidates include SLN124 for hematological diseases and zerlasiran (formerly SLN360) for reducing cardiovascular risk in people born with high levels of lipoprotein(a), a genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after.
Partnerships
Silence Therapeutics is under the stewardship of CEO Craig Tooman, and has established partnerships with pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.
“Silence Therapeutics” enters the record as uK business. Crown Archives preserves that source wording while asking what Silence, Therapeutics and business can confirm, complicate or overturn.
Why this record matters
“Silence Therapeutics” is worth following because a concise public description often conceals a longer documentary argument. Here, Silence, Therapeutics and business provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 24, 2026. The linked authority identifier is Q7514392. 2 of 2 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 1994 and 2023.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Silence Therapeutics”, its source revision and the description used here.
- Expand the search: follow Silence Therapeutics primary sources, Silence Therapeutics archive and Silence research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Silence Therapeutics”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Silence Therapeutics” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.